Global Hadron Therapy Market - 2023-2030

Global Hadron Therapy Market - 2023-2030

Global hadron therapy market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Hadron therapy, also known as particle therapy, is an advanced cancer treatment that uses charged particles, such as protons and heavy ions, to target and destroy cancer cells with exceptional accuracy while minimizing harm to surrounding healthy tissue. Unlike conventional radiation therapy, which uses X-rays or gamma rays, hadron therapy's unique ability to deposit most of its energy at a specific depth within the body, called the Bragg peak, makes it highly effective for treating specific types of tumors.

This therapy has gained much attention for its potential to reduce side effects and improve the quality of life for cancer patients, particularly in cases where tumors are located near critical organs or in pediatric patients. It represents a state-of-the-art approach to cancer treatment, offering new hope to many individuals fighting this disease.

Market Dynamics: Drivers and Restraints

Advancement in laser-powered proton therapy for cancer treatment is expected to drive market growth

In March 2022, a recent report from Berkeley Lab News Center highlights a project that aims to develop a more compact and cost-effective proton therapy system by adapting the technology of laser-driven ion accelerators. In addition, the scientific community is exploring the potential benefits of using these accelerators for FLASH radiotherapy, which involves delivering proton beam radiation at ultrahigh doses within extremely short exposure times.

Proton therapy is a type of radiation therapy that uses protons instead of X-rays to painlessly treat certain types of cancer. However, conventional proton therapy systems tend to be large and expensive, making them less accessible to patients. The ongoing project at Berkeley Lab aims to overcome this problem by utilizing laser-generated proton beams to create a more efficient and affordable form of radiation therapy.

The Lawrence Berkeley National Laboratory (Berkeley Lab) is conducting a project that involves collaboration between biologists and physicists. Researchers at the Berkeley Lab Laser Accelerator (BELLA) Center are working together with the scientists to test how living tissue responds to laser-driven (LD) proton beams at FLASH dose rates. The BELLA scientists will use this opportunity as a real-world application to refine their experimental laser platform while the biologists will test the proton beam radiation therapy at ultrahigh doses within extremely short exposure times.

However, more research is needed to determine its safety and efficacy. Therefore, the use of laser technology in cancer treatment is a highly promising development in the field of Hadron Therapy. Berkeley Lab's ongoing project aims to make proton therapy more accessible, affordable, and effective. The potential advantages of using laser-generated proton beams to deliver FLASH radiotherapy are significant, but additional research is required to determine its safety and effectiveness.

Restraint:

The high initial capital costs associated with building and maintaining hadron therapy facilities can be a significant barrier, limited availability of hadron therapy centers, and scarcity of skilled personnel are the factors expected to hamper the market over the forecast period.

For more details on this report – Request for Sample

Segment Analysis

The global hadron therapy market is segmented based on type of particle radiation, application, end-user and region.

The proton beam from the type of particle radiation segment accounted for approximately 45.5% of the hadron therapy market share

Proton beam therapy is a leading treatment modality in the field of hadron therapy. It is highly effective in treating various types of cancer with precision. The therapy's primary advantage is that it allows for precise control of the depth at which the protons deposit their maximum energy, thereby minimizing damage to healthy tissues beyond the tumor site. This accuracy helps to reduce the risk of side effects and complications, making it particularly beneficial for pediatric patients and cases involving tumors located near critical organs.

The market for proton beam therapy is driven by increasing cancer incidence rates, product launches by the market players, rising clinical trials of FLASH proton therapy, growing awareness of its benefits, and the desire to improve patients' quality of life during and after treatment.

For instance, on February 1, 2022, Hitachi, Ltd. announced that the Shonan Kamakura Advanced Medical Center at Shonan Kamakura General Hospital of Tokushukai Medical Group started treating patients with Hitachi's compact proton therapy system.

Shonan Kamakura Advanced Medical Center is a medical facility that offers comprehensive cancer treatment, including advanced radiotherapy. The center was built next to the Shonan Kamakura General Hospital by Tokushukai Group Medical Corporation, which operates around 400 medical facilities and nursing homes across Japan.

Geographical Analysis

North America accounted for approximately 41.3% of the market share in 2022

North America is expected to hold the largest market share, owing to the increasing prevalence of cancer, expansion of therapy centers, increasing awareness about hadron therapy and increasing collaboration among the research centers.

For instance, South Jersey's first proton therapy center opened on the Virtua Voorhees Hospital Campus. The 8,600-square-foot facility offers a full range of services, including evaluation, treatment, and access to clinical trials. Proton therapy uses protons to deliver high doses of radiation to tumors while minimizing damage to surrounding healthy tissue. The proton therapy center is a collaboration between Penn Medicine and Virtua Health, and it is one of only about 40 such centers nationwide.

The facility is equipped with state-of-the-art technology, including a cyclotron and a gantry. While there is limited research comparing its effectiveness to traditional radiation therapy, the opening of South Jersey's first proton therapy center is a significant development in cancer treatment in the region, and it offers new hope to patients who may benefit from this type of therapy.

COVID-19 Impact Analysis

The COVID-19 pandemic had a mixed impact on the hadron therapy market, a specialized cancer treatment. On the bright side, the pandemic has increased awareness about healthcare vulnerabilities and the significance of advanced and precise cancer treatments like hadron therapy. As a result, research and technological innovations in the field have been accelerated, potentially leading to advancements in treatment protocols.

However, the pandemic has also caused hurdles in the construction and operation of new hadron therapy facilities due to restrictions, resource reallocation, and logistical challenges. These factors may slow the market's growth. Moreover, the economic consequences of the pandemic have affected healthcare budgets, which may impact the investment in expensive hadron therapy centers.

Market Segmentation:

By Type of Particle Radiation
• Alpha Particle Beam
• Proton Beam
• Carbon Ion Beam
• Electron Beam
• Neutron Beam
• Beta Particle Beam

By Application
• Prostate Cancer
• Liver Cancer
• Head & Neck Cancer
• Bone & Soft Tissue Cancer
• Lung Cancer
• Others

By End-User
• Hospitals
• Cancer Treatment Centers
• Ambulatory Surgical Centers
• Research Institutions
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the hadron therapy market include Optivus Proton Therapy, Inc., Hitachi, Ltd., Sumitomo Heavy Industries, Ltd., Elekta, Advanced Oncotherapy, Varian Medical Systems, Inc., Mevion Medical Systems, Provision Healthcare, ProTom International, and Koninklijke Philips N.V. among others.

Key Development
• On November 3, 2022, Mevion Medical Systems, which is the top provider of compact proton therapy systems for radiation treatment of cancer patients, stated that it is currently working on its latest product, the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS). The system will be developed and installed at Stanford Health Care, which has been selected as the first site for this installation.
• On October 31, 2022, Varian, a Siemens Healthineers company, and the Cincinnati Children's/University of Cincinnati Medical Center Proton Therapy Center published clinical trial results from FAST-01, the first clinical trial of ultra-high dose rate Flash therapy and the first-in-human experience of proton Flash.
• On May 5, 2022, IBA, a leading company in particle accelerator technology and the world's primary provider of proton therapy solutions for cancer treatment, received an order from CGN Medical Technologies for a Proteus PLUS proton therapy system. The system will be installed in Yangzhou, China, and this order marks the first project under the collaboration between IBA and CGNNT, which was announced in August 2020.

Why Purchase the Report?
• To visualize the global hadron therapy segmentation based on type of particle radiation, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of hadron therapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global hadron therapy market report would provide approximately 61 tables, 66 figures, and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies